急性髓系白血病的分子靶向治疗：第57届美国血液学会年会报道

Molecularly targeted therapies for acute myeloid leukemia：reports from the 57th American Society of Hematology annual meeting

21世纪以来，基因突变在急性髓系白血病（AML）发生、发展中的作用越来越受到重视。针对FLT3-ITD和IDH等突变基因的靶向药物的临床试验正在进行中。文章就第57届美国血液学会年会报道的靶向特异性基因突变和（或）表观遗传学异常的临床试验中的几种药物进行介绍。

Sina 21 century it have seen major leaps in the understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia （AML）. Clinical trials of targeted drugs against specific mutant proteins, such as FLT3-internal tandem duplications （ITD） and isocitrate dehydrogenase mutations （IDH） are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets from the 57th American Society of Hematology annual meeting.